Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repligen Corp RGEN

Technology Scientific & Technical Instruments
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial... see more

Recent & Breaking News (NDAQ:RGEN)

Repligen Reports Third Quarter 2024 Financial Results

GlobeNewswire November 12, 2024

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire November 5, 2024

Repligen to Report Third Quarter 2024 Financial Results

GlobeNewswire October 31, 2024

Repligen Opens Training & Innovation Center to Elevate Customer Experience

GlobeNewswire September 24, 2024

Repligen Corporation to Present at Wells Fargo Healthcare Conference

GlobeNewswire August 23, 2024

Repligen Reports Second Quarter 2024 Financial Results

GlobeNewswire July 30, 2024

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

GlobeNewswire July 29, 2024

Repligen to Report Second Quarter 2024 Financial Results

GlobeNewswire July 16, 2024

The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Contact Them

Accesswire June 20, 2024

Repligen Announces CEO Transition Plan

GlobeNewswire June 13, 2024

Repligen Corporation to Present at Upcoming June Investor Conferences

GlobeNewswire May 22, 2024

Repligen Corporation to Present at Upcoming May Investor Conferences

GlobeNewswire May 7, 2024

Repligen Reports First Quarter 2024 Financial Results

GlobeNewswire May 1, 2024

Repligen to Report First Quarter 2024 Financial Results

GlobeNewswire April 17, 2024

Repligen Appoints Maggie A. Pax to Board of Directors

GlobeNewswire March 19, 2024

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 21, 2024

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 7, 2024

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2023

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

GlobeNewswire December 7, 2023

UPDATE - Repligen Announces Publication of the Company's 2022 Sustainability Report

GlobeNewswire November 14, 2023